These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38786052)

  • 21. Effect of Trinucleotide Repeats in the Huntington's Gene on Intelligence.
    Lee JK; Conrad A; Epping E; Mathews K; Magnotta V; Dawson JD; Nopoulos P
    EBioMedicine; 2018 May; 31():47-53. PubMed ID: 29685790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosomal instability during neurogenesis in Huntington's disease.
    Ruzo A; Croft GF; Metzger JJ; Galgoczi S; Gerber LJ; Pellegrini C; Wang H; Fenner M; Tse S; Marks A; Nchako C; Brivanlou AH
    Development; 2018 Jan; 145(2):. PubMed ID: 29378824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan.
    Kielar C; Morton AJ
    J Huntingtons Dis; 2018; 7(1):61-76. PubMed ID: 29480204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods for Assessing DNA Repair and Repeat Expansion in Huntington's Disease.
    Massey T; McAllister B; Jones L
    Methods Mol Biol; 2018; 1780():483-495. PubMed ID: 29856032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
    Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Therapy for Huntington's Disease Using Targeted Endonucleases.
    Dabrowska M; Olejniczak M
    Methods Mol Biol; 2020; 2056():269-284. PubMed ID: 31586354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Huntington's disease: how intermediate are intermediate repeat lengths?
    Squitieri F; Jankovic J
    Mov Disord; 2012 Dec; 27(14):1714-7. PubMed ID: 23008174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Triplet-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats in the Huntingtin Gene (
    De Luca A; Morella A; Consoli F; Fanelli S; Thibert JR; Statt S; Latham GJ; Squitieri F
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
    Mariani LL; Tesson C; Charles P; Cazeneuve C; Hahn V; Youssov K; Freeman L; Grabli D; Roze E; Noël S; Peuvion JN; Bachoud-Levi AC; Brice A; Stevanin G; Durr A
    JAMA Neurol; 2016 Sep; 73(9):1105-14. PubMed ID: 27400454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.
    Matthes F; Massari S; Bochicchio A; Schorpp K; Schilling J; Weber S; Offermann N; Desantis J; Wanker E; Carloni P; Hadian K; Tabarrini O; Rossetti G; Krauss S
    ACS Chem Neurosci; 2018 Jun; 9(6):1399-1408. PubMed ID: 29506378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length Variation.
    Ciosi M; Cumming SA; Chatzi A; Larson E; Tottey W; Lomeikaite V; Hamilton G; Wheeler VC; Pinto RM; Kwak S; Morton AJ; Monckton DG
    J Huntingtons Dis; 2021; 10(1):53-74. PubMed ID: 33579864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S; Reardon HT; Yin K; Mosier C; Hook V
    J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
    Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
    Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.